<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83373">
  <stage>Registered</stage>
  <submitdate>18/11/2008</submitdate>
  <approvaldate>27/05/2009</approvaldate>
  <actrnumber>ACTRN12609000368235</actrnumber>
  <trial_identification>
    <studytitle>The effect of Oxytocin (OT) on social cognition and behaviour in youth with Autism Spectrum Disorders (ASD).</studytitle>
    <scientifictitle>THe effects of Oxytocin in young people with Autism to treat social communication problems</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Therapeutic Goods Association Clinical Trial Notification (TGA CTN): 2008/596</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Autism</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Autistic spectrum disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Young people with Autism Spectrum Disorders are given a single dose of oxytocin nasal spray or an identical placebo  in a crossover design with a one-week washout period. For children between the age of 12 and 15 we use a 18 International Unit dose, while people between the age of 16 and 20 receive a 24 International Unit dose. Participants receive the nasal spray, wait 45 minutes and complete experimental tasks. Participants return one week later to receive the nasal spray again, wait 45 minutes and complete the same experimental tasks. On both occasions participants are observed for a period of 1.5 hours while they complete social cognition tasks. These tasks include emotion recognition (Reading the mind in the eyes) as well as eye-tracking when viewing human faces. The entire trial is completed within these two experimental testing sessions.</interventions>
    <comparator>The placebo nasal spray is a solution containing all of the ingredients used in the OT nasal spray except the active OT. It is administered 45 minutes before participants complete experimental cognition tasks. The placebo is administered once in exactly the same manner as the OT spray. Participants receive 18IU for 12 - 15 year olds and 24 IU for 16 to 20 year olds.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Performance on emotion recognition (Reading the mind in the eyes test)</outcome>
      <timepoint>Assessed 45 minutes post nasal spray administration.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Side effect reports noted from participants</outcome>
      <timepoint>Assessed 45 minutes post nasal spray administration.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male youth with a primary diagnosis of Autism or Asperger disorder with a mental age of 12 or higher.</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>20</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Females, mental age below 12. Chronological age below 12.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Drug allocation concealment is conducted by numbering all containers</concealment>
    <sequence>Random number generation using computer software. Each number is labelled with 'a' or 'b' where a or b could represent either Oxytocin or Placebo in a cross-over design.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>All subjects, assessors, therapists, and data entry staff are blind to drug condition</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/10/2008</anticipatedstartdate>
    <actualstartdate>3/10/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>13/03/2009</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress>94 Mallett St
Camperdown, Sydney, NSW, 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study tests whether Oxytocin improves the social communication problems in young people with Autism. It is predicted that individuals from the community diagnosed with autism or asperger's disorder who receive a single dose of oxytocin nasal spray will show improved performance on social cognition tests in comparison to performance on these tests under a placebo. Two single session assessment sessions within a two week period are conducted using a crossover design. All subjects, therapists, assessors, and data entry staff are blind to condition.</summary>
    <trialwebsite>None</trialwebsite>
    <publication>Published Manuscript:

Guastella, A.J., Einfeld, S.E., Gray, K., Rinehart, N., Tonge, B., Lambert, T., &amp; Hickie, I.B. (2010). Oxytocin improves      emotion recognition for youth with Autism. Biological Psychiatry, 67(7):692-4. </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Sydney Human Research Ethics Committee</ethicname>
      <ethicaddress>Human Research Ethics Comittee,
Level 6, Jane Foss Russell Building G02
The University of Sydney, Darlington, NSW, 2006</ethicaddress>
      <ethicapprovaldate>14/05/2008</ethicapprovaldate>
      <hrec>10755</hrec>
      <ethicsubmitdate>1/02/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Adam Guastella</name>
      <address>Brain &amp; Mind Research Institute, 
University of Sydney, 94 Mallett St, Camperdown, NSW, 2050</address>
      <phone>+61 2 9351 0539</phone>
      <fax>+61 2 9351 0881</fax>
      <email>adam.guastella@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Adam Guastella</name>
      <address>Brain &amp; Mind Research Institute, 
University of Sydney, 94 Mallett St, Camperdown, NSW, 2050</address>
      <phone>+61 2 9351 0539</phone>
      <fax>+61 2 9351 0881</fax>
      <email>adam.guastella@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Adam Guastella</name>
      <address>Brain &amp; Mind Research Institute, 
University of Sydney, 94 Mallett St, Camperdown, NSW, 2050</address>
      <phone>+61 2 9351 0539</phone>
      <fax>+61 2 9351 0881</fax>
      <email>adam.guastella@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Adam Guastella</name>
      <address>Brain &amp; Mind Research Institute, University of Sydney, 94 Mallett St, Camperdown, NSW, 2050</address>
      <phone>+61 2 9351 0539</phone>
      <fax />
      <email>adam.guastella@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>